Advertisement
Advertisement
BNGO
Bionano Genomics, Inc. Common Stock
0.95
USDSponsored
+0.02
+2.50%
Nov 18, 15:56 UTC -5
Closed
Pre-Market
0.97
+0.02
+1.99%
Bionano Genomics, Inc. Common Stock (BNGO) Earnings
BNGO Earnings Reports
Positive Surprise Ratio
BNGO beat 13 of 33 last estimates.
39%
Next Report
Date of Next Report
Mar 22, 2027
Estimate for Q4 26 (Revenue/ EPS)
$9.36M
/-$0.45
Implied change from Q3 26 (Revenue/ EPS)
+13.04%
/-16.67%
Implied change from Q4 25 (Revenue/ EPS)
+17.66%
/+1400.00%
Bionano Genomics, Inc. Common Stock earnings per share and revenue
On Nov 10, 2026, BNGO reported earnings of -0.54 USD per share (EPS) for Q3 26, missing the estimate of -0.49 USD, resulting in a -8.04% surprise. Revenue reached 8.28 million, compared to an expected 8.61 million, with a -3.90% difference. The market reacted with a -10.57% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.45 USD, with revenue projected to reach 9.36 million USD, implying an decrease of -16.67% EPS, and increase of 13.04% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Rein Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%

Instil Bio, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.17
Actual
-$0.62
Surprise
-261.09%

Estrella Immunopharma, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.17
Surprise
-108.33%

AYTU BioPharma, Inc. Common Stock
Report Date
Nov 16, 2026 For Q1 27
Estimate
-$0.26
Actual
-$0.20
Surprise
+23.61%

Jasper Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.02
Actual
-$13.97
Surprise
-361.93%

Kyntra Bio, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.61
Actual
-$3.42
Surprise
+5.49%

Lantern Pharma Inc. Common Stock
Report Date
Nov 17, 2026 For Q3 26
Estimate
-$0.35
Actual
-$0.81
Surprise
-126.89%

Pulmatrix, Inc. Common Stock
Report Date
Nov 17, 2026 For Q3 26
Estimate
-Actual
-$0.34
Surprise
-

Senti Biosciences Holdings, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.30
Actual
-$0.37
Surprise
-22.96%

MapLight Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$1.19
Actual
-$0.97
Surprise
+18.86%
FAQ
What were Bionano Genomics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Bionano Genomics, Inc. Common Stock reported EPS of -$0.54, missing estimates by -8.04%, and revenue of $8.28M, -3.9% below expectations.
How did the market react to Bionano Genomics, Inc. Common Stock's Q3 2026 earnings?
The stock price moved down -10.57%, changed from $1.23 before the earnings release to $1.10 the day after.
When is Bionano Genomics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 22, 2027.
What are the forecasts for Bionano Genomics, Inc. Common Stock's next earnings report?
Based on --
analysts, Bionano Genomics, Inc. Common Stock is expected to report EPS of -$0.45 and revenue of $9.36M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.